Otsuka Holdings Co., Ltd. (OTSKF)
USD 57.15
(0.0%)
USD 57.15
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -299.15 Billion JPY | -7.81% |
| 2022 | -277.47 Billion JPY | -39.97% |
| 2021 | -198.23 Billion JPY | -51.59% |
| 2020 | -130.77 Billion JPY | -62.0% |
| 2019 | -80.72 Billion JPY | -2.01% |
| 2018 | -79.13 Billion JPY | 16.86% |
| 2017 | -95.18 Billion JPY | 1.51% |
| 2016 | -96.63 Billion JPY | 18.15% |
| 2015 | -118.06 Billion JPY | 67.59% |
| 2014 | -364.31 Billion JPY | -4.72% |
| 2013 | -347.89 Billion JPY | -3.18% |
| 2012 | -337.18 Billion JPY | -14.25% |
| 2011 | -295.12 Billion JPY | -79.54% |
| 2010 | -164.38 Billion JPY | -70.53% |
| 2009 | -96.39 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -212.15 Billion JPY | 29.08% |
| 2024 Q2 | -237.92 Billion JPY | -12.15% |
| 2023 FY | -299.15 Billion JPY | -7.81% |
| 2023 Q2 | -310.97 Billion JPY | -8.52% |
| 2023 Q3 | -333.73 Billion JPY | -7.32% |
| 2023 Q4 | -299.15 Billion JPY | 10.36% |
| 2023 Q1 | -286.55 Billion JPY | -3.27% |
| 2022 Q2 | -247.72 Billion JPY | -17.13% |
| 2022 Q1 | -211.48 Billion JPY | -6.69% |
| 2022 Q3 | -271.73 Billion JPY | -9.69% |
| 2022 FY | -277.47 Billion JPY | -39.97% |
| 2022 Q4 | -277.47 Billion JPY | -2.11% |
| 2021 FY | -198.23 Billion JPY | -51.59% |
| 2021 Q3 | -229.12 Billion JPY | -9.29% |
| 2021 Q4 | -198.23 Billion JPY | 13.48% |
| 2021 Q1 | -167.51 Billion JPY | -28.09% |
| 2021 Q2 | -209.65 Billion JPY | -25.16% |
| 2020 Q1 | -84.08 Billion JPY | -4.16% |
| 2020 Q2 | -99.98 Billion JPY | -18.91% |
| 2020 Q3 | -103.72 Billion JPY | -3.74% |
| 2020 Q4 | -130.77 Billion JPY | -26.08% |
| 2020 FY | -130.77 Billion JPY | -62.0% |
| 2019 Q2 | -43.14 Billion JPY | -391.53% |
| 2019 Q4 | -80.72 Billion JPY | -23.14% |
| 2019 Q1 | 14.79 Billion JPY | 118.7% |
| 2019 Q3 | -65.55 Billion JPY | -51.94% |
| 2019 FY | -80.72 Billion JPY | -2.01% |
| 2018 Q2 | -60.19 Billion JPY | 18.47% |
| 2018 Q4 | -79.13 Billion JPY | -115.29% |
| 2018 Q3 | -36.75 Billion JPY | 38.94% |
| 2018 Q1 | -73.83 Billion JPY | 22.43% |
| 2018 FY | -79.13 Billion JPY | 16.86% |
| 2017 Q2 | -121.16 Billion JPY | -89.83% |
| 2017 FY | -95.18 Billion JPY | 1.51% |
| 2017 Q3 | -73.57 Billion JPY | 39.28% |
| 2017 Q4 | -95.18 Billion JPY | -29.36% |
| 2017 Q1 | -63.82 Billion JPY | 33.95% |
| 2016 Q1 | -169.23 Billion JPY | -43.34% |
| 2016 FY | -96.63 Billion JPY | 18.15% |
| 2016 Q3 | -241.18 Billion JPY | -15.85% |
| 2016 Q4 | -96.63 Billion JPY | 59.93% |
| 2016 Q2 | -208.19 Billion JPY | -23.02% |
| 2015 Q3 | -181.71 Billion JPY | -23.86% |
| 2015 FY | -118.06 Billion JPY | 67.59% |
| 2015 Q4 | -118.06 Billion JPY | 35.03% |
| 2015 Q2 | -146.71 Billion JPY | -224.79% |
| 2015 Q1 | -45.17 Billion JPY | 0.0% |
| 2014 Q2 | -324.09 Billion JPY | 14.64% |
| 2014 FY | -364.31 Billion JPY | -4.72% |
| 2014 Q3 | -360.81 Billion JPY | -11.33% |
| 2014 Q1 | -379.66 Billion JPY | -4.01% |
| 2013 Q2 | -346.19 Billion JPY | 0.49% |
| 2013 FY | -347.89 Billion JPY | -3.18% |
| 2013 Q4 | -365.04 Billion JPY | 16.6% |
| 2013 Q3 | -437.72 Billion JPY | -26.44% |
| 2013 Q1 | -347.89 Billion JPY | -0.79% |
| 2012 Q4 | -345.16 Billion JPY | 2.88% |
| 2012 Q2 | -335.27 Billion JPY | 0.57% |
| 2012 FY | -337.18 Billion JPY | -14.25% |
| 2012 Q1 | -337.18 Billion JPY | -7.97% |
| 2012 Q3 | -355.4 Billion JPY | -6.0% |
| 2011 FY | -295.12 Billion JPY | -79.54% |
| 2011 Q1 | -295.12 Billion JPY | -16.21% |
| 2011 Q2 | -328.96 Billion JPY | -11.47% |
| 2011 Q3 | -349.55 Billion JPY | -6.26% |
| 2011 Q4 | -312.29 Billion JPY | 10.66% |
| 2010 Q1 | -164.38 Billion JPY | -12.89% |
| 2010 Q4 | -253.94 Billion JPY | -29.6% |
| 2010 Q3 | -195.95 Billion JPY | -33.74% |
| 2010 Q2 | -146.52 Billion JPY | 10.86% |
| 2010 FY | -164.38 Billion JPY | -70.53% |
| 2009 Q4 | -145.6 Billion JPY | 15.92% |
| 2009 Q3 | -173.18 Billion JPY | -12.75% |
| 2009 FY | -96.39 Billion JPY | 0.0% |
| 2009 Q2 | -153.6 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 1414.972% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 1097.18% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | -18667.027% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 1887030.743% |
| Novartis AG | 12.95 Billion USD | 2409.178% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | -176182.396% |